Zahari Zalina, Salleh Mohd Razali, Teh Lay Kek, Ismail Rusli
Pharmacogenetics Research Group, Institute for Research in Molecular Medicine (INFORMM), Universiti Sains Malaysia Health Campus & Department of Pharmacy, Hospital Universiti Sains Malaysia, Universiti Sains Malaysia Health Campus, Jln Raja Perempuan Zainab II, 16150 Kubang Kerian, Kelantan, Malaysia.
Malays J Med Sci. 2009 Jul;16(3):12-20.
Our objective was to investigate the association of CYP2D6 polymorphisms with symptoms and side-effects of patients with schizophrenia.
The subjects were 156 patients with schizophrenia undergoing antipsychotic treatment at a psychiatric clinic. Patients with co-morbid diagnoses of substance abuse or mental retardation were excluded from the study. Psychopathology was evaluated using the Positive and Negative Symptoms Scale (PANSS). Extrapyramidal side-effects and akathisia were assessed with the Simpson Angus Scale (SAS) and the Barnes Akathisia Rating Scale (BARS), respectively. DNA was extracted from blood and subjected to PCR-genotyping.
We found that CYP2D6 polymorphisms were significantly associated with a subtotal negative PANSS score. In addition, CYP2D6 is not related to side-effects of antipsychotic therapy, or SAS and BARS scores. The results suggest that CYP2D6 polymorphisms may have implications in treatment response.
Therefore, CYP2D6 may be a predictor for treatment outcomes of patients with schizophrenia. However, further investigation is required to confirm these findings in a larger sample.
我们的目的是研究CYP2D6基因多态性与精神分裂症患者症状及副作用之间的关联。
研究对象为156名在精神科诊所接受抗精神病药物治疗的精神分裂症患者。共病有药物滥用或智力发育迟缓诊断的患者被排除在研究之外。使用阳性和阴性症状量表（PANSS）评估精神病理学。分别使用辛普森·安格斯量表（SAS）和巴恩斯静坐不能评定量表（BARS）评估锥体外系副作用和静坐不能。从血液中提取DNA并进行PCR基因分型。
我们发现CYP2D6基因多态性与PANSS总分阴性显著相关。此外，CYP2D6与抗精神病治疗的副作用或SAS和BARS评分无关。结果表明CYP2D6基因多态性可能对治疗反应有影响。
因此，CYP2D6可能是精神分裂症患者治疗结果的一个预测指标。然而，需要进一步研究以在更大样本中证实这些发现。
